Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene Products

2 Mar 1990

Abstract excerpt

Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 2408149
DOI: 10.1126/science.2408149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene ProductsPMID 2408149Read ↗

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.Semantic proximity Read ↗

Bcr-Abl variants: biological and clinical aspects.Semantic proximity Read ↗

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.Semantic proximity Read ↗

Exon-skipping in BCR/ABL is induced by ABL exon 2.Semantic proximity Read ↗

The 5' non-coding region of the BCR/ABL oncogene augments its ability to stimulate the growth of immature lymphoid cells.Semantic proximity Read ↗

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.Semantic proximity Read ↗

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.Semantic proximity Read ↗

Oncogenic activation of c-ABL by mutation within its last exon.Semantic proximity Read ↗

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.Semantic proximity Read ↗

The P190, P210, and P230 Forms of the <i>BCR/ABL</i> Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivitySemantic proximity Read ↗

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.Semantic proximity Read ↗

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.